# Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 (the AMMURAVID Trial)

> **NCT04832880** · PHASE3 · UNKNOWN · sponsor: **ASST Fatebenefratelli Sacco** · enrollment: 4000 (estimated)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Baricitinib Oral Tablet [Olumiant]
- **DRUG:** Remdesivir
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT04832880
- **Lead sponsor:** ASST Fatebenefratelli Sacco
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-06
- **Primary completion:** 2022-03
- **Final completion:** 2022-12
- **Target enrollment:** 4000 (ESTIMATED)
- **Last updated:** 2021-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04832880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04832880, "Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 (the AMMURAVID Trial)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04832880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*